YOLFTbeta
Hangzhou Biotest Biotech Co Ltd

Hangzhou Biotest Biotech Co Ltd

688767 · SHG · Healthcare / Biotechnology

39.26CNY+0.43 (+1.11%)

Price History

Full chart

Market Stats

Previous Close38.83
Open38.80
Day Range38.33 – 39.76
52-Week Range29.84 – 50.04
Volume1.97M
Market Cap6.00B
P/E (TTM)251.25
Forward P/E0.00
EPS0.16
Dividend Yield1.74%
Beta0.66
50-Day Avg38.91
200-Day Avg37.72

About

Hangzhou Biotest Biotech Co.,Ltd., together with its subsidiaries, engages in the research, development, production, sale, and service of in vitro diagnostic reagents in China and internationally. The company offers point-of-care testing rapid diagnostic reagents for drug abuse, infectious disease, fertility health, tumor market/oncology, cardiology market, veterinary, inflammation, and other testing. It also provides microfluidic immunofluorescence analysis systems; and Diagpal SE and Diagpal lateral flow readers. In addition, the company engages in investing activities. Its products are used across various medical institutions, judicial testing systems, third-party testing organizations, centers for disease control and prevention (CDC), and private clinics. Hangzhou Biotest Biotech Co.,Ltd. was founded in 2008 and is headquartered in Hangzhou, China.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Shujiang Wu
  • Employees598
  • HeadquartersNo. 27, Tuyi Road, Hangzhou, China, 311100, China
  • Websitehttps://www.biotests.com.cn

Leadership

  • Mr. Shujiang WuGM & Director · b. 1977
  • Ms. Miao Miao YuAccounting Supervisor & Financial Director · b. 1981
  • Mr. Yujie ChenDeputy GM & Director · b. 1990
  • Mr. Chun Sheng YeDeputy GM & Director · b. 1976
  • Mr. Qi Jun FeiDeputy GM & Secretary of the Board of Directors · b. 1981
  • Mr. Chao LiuDeputy General Manager · b. 1984

Financials

Income Statement

Currency: CNY2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue121.77M180.30M208.84M865.37M1.82B1.90B442.11M559.40M448.37M
Growth (%)-+48.07%+15.83%+314.37%+110.09%+4.57%-76.75%+26.53%-19.85%
Cost of Revenue79.58M115.73M121.64M242.57M705.47M940.21M269.60M286.60M241.78M
Gross Profit42.19M64.57M87.20M622.80M1.11B960.93M172.51M272.81M448.37M
Gross Margin34.65%35.81%41.75%71.97%61.20%50.54%39.02%48.77%100.00%
Operating Expense37.93M42.03M54.97M109.72M146.09M46.59M55.69M79.40M398.32M
Operating Income4.26M22.55M32.23M513.08M966.52M914.34M116.82M193.41M50.05M
Operating Margin3.50%12.51%15.43%59.29%53.16%48.09%26.42%34.57%11.16%
EBITDA8.21M28.02M38.30M520.28M978.18M921.99M141.39M218.04M70.47M
EBITDA Margin6.74%15.54%18.34%60.12%53.80%48.50%31.98%38.98%15.72%
Net Income4.03M18.91M28.23M435.15M833.59M773.63M106.61M169.52M46.80M
Net Income Margin3.31%10.49%13.52%50.28%45.85%40.69%24.11%30.30%10.44%
R&D10.85M9.67M16.85M41.32M61.92M108.21M80.48M63.57M83.48M
R&D as % of Total Revenue8.91%5.36%8.07%4.78%3.41%5.69%18.20%11.36%18.62%
Interest Expense629.49K1.36M1.19M1.00M1.36M1.19M838.55K1.85M-
Interest Expense % of Total Revenue0.52%0.75%0.57%0.12%0.07%0.06%0.19%0.33%-

Balance Sheet

Currency: CNY2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets127.52M154.63M210.44M633.92M2.43B2.75B2.58B2.60B2.54B
Total Liabilities47.88M56.48M84.50M190.89M323.36M188.92M158.82M189.79M168.17M
Total Equity80.25M98.86M126.96M444.14M2.11B2.56B2.42B2.41B2.37B
Cash8.90M16.34M13.81M261.17M1.37B1.94B1.91B1.59B1.48B
Total Debt20.13M20.09M32.13M11.09M12.47M7.64M588.77K440.52K-
Net Debt11.23M3.76M18.32M-250.08M-1.36B-1.93B-1.90B-1.59B-

Cash Flow

Currency: CNY2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow7.07M21.17M25.67M446.07M908.12M703.21M131.38M128.83M106.47M
Investing Cash Flow-15.38M-12.61M-39.47M-56.08M-599.97M96.71M74.36M-838.25M-
Financing Cash Flow11.58M-1.01M10.94M-124.92M813.24M-332.65M-249.19M-104.55M-
Capital Expenditure26.37M12.67M39.47M57.68M200.20M178.92M56.42M245.05M129.87M
Free Cash Flow-19.30M8.50M-13.81M388.38M707.92M524.29M74.96M-116.23M-23.40M
Dividends Paid610.40K883.15K1.08M100.38M20.91M320.00M234.67M83.65M159.88M
FCF to OCF-272.80%40.16%-53.79%87.07%77.95%74.56%57.05%-90.22%-21.98%
Dividend Paid to FCF-3.16%10.39%-7.84%25.85%2.95%61.03%313.07%-71.97%-683.15%

Earnings

Report DateSep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023
EPS Estimate-------
EPS Actual1.411.074.622.371.31-1.040.11
Surprise-------
Timing-------

Key Statistics & Ratios

Market Cap6.00B
Enterprise Value5.32B
Trailing P/E251.25
Forward P/E0.00
Price / Sales13.07
Price / Book3.03
EPS0.16
Book Value13.80
Revenue (TTM)459.42M
Gross Profit (TTM)205.16M
EBITDA35.02M
Profit Margin4.42%
Operating Margin0.17%
Return on Equity0.86%
Return on Assets0.28%
Shares Outstanding149.33M
Shares Float60.19M
Beta0.66
Dividend Yield1.74%
Dividend Rate0.70
Payout Ratio437.50%

Dividends

20261×
0.70Jun 1, 2026
20252×
0.71Jun 6, 20250.36Jan 10, 2025
20241×
0.57Jun 11, 2024
20231×
1.57Jun 9, 2023
20221×
2.14Jun 8, 2022

Stock Splits

  • Jun 6, 20251.4:1